September 30, 2016 Bio/Pharma/CRO Licensing, IP, and Legal Product Launch

GE Healthcare’s Biosafe announces Sefia platform to address multiple steps in cell therapy production process

CHALFONT ST. GILES, UK – 30 September 2016 –At the International Society for Cellular Therapy’s Regional Meeting in Memphis, TN, GE Healthcare’s recently acquired Biosafe Group introduces Sefia, a state-of-the-art, multi-function platform which uses a combination of continuous-flow centrifugation, temperature control and fluidic management to enable purification, concentration, washing  and final formulation during cell processing. Combined with GE... Read more

September 29, 2016 Cell Analysis Tools Licensing, IP, and Legal

Miltenyi Biotec acquires exclusive rights for the distribution and development of the viral transduction enhancer Vectofusin-1® from Genethon

Evry, France, and Bergisch Gladbach, Germany, September 28th, 2016 – Genethon, a leader in the field of gene therapy treatments for rare diseases, and Miltenyi Biotec, a global front-runner in cell processing and related technologies in cell therapy, have announced the execution of an exclusive license to the patents and trademarks for the development and commercialization... Read more

September 5, 2016 Licensing, IP, and Legal M&A, Partnerships

Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet

Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiac Progenitor Cells iCell Neurons iCell Astrocytes iCell DopaNeurons iCell GlutaNeurons iCell Hepatocytes 2.0 iCell Hepatoblasts iCell Skeletal Myoblasts iCell Endothelial Cells... Read more

August 23, 2016 Clinical Research/Diagn. Industrial Licensing, IP, and Legal

GE Healthcare expands cell therapy portfolio with license of STEMCELL Technologies’ T-Cell reagents

Chalfont St Giles, UK – 23 August 2016 – In a further step to build its portfolio for the rapidly-growing cell therapy industry, GE Healthcare today announced an agreement with STEMCELL Technologies Inc. of Vancouver, Canada to provide T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of... Read more

June 21, 2016 Bio/Pharma/CRO Licensing, IP, and Legal M&A, Partnerships

Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma

Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma Kusatsu/Shiga, Japan — June 21, 2016 – Takara Bio Inc. announces that it has entered into a License and Supply Agreement with Kite Pharma, Inc. (“Kite”), United States, under which Takara Bio grants Kite a commercial license to use applicable patents relating... Read more

June 8, 2016 Licensing, IP, and Legal

PnuVax to acquire inactivated yellow fever vaccine intellectual property from GE Healthcare

CHALFONT ST. GILES, UK and KINGSTON, ONTARIO, CANADA – 8 June 2016 – PnuVax Incorporated (PnuVax), a vaccine and biopharmaceutical company, and GE Healthcare’s Life Sciences business (NYSE: GE) announced today that they have entered an agreement under which PnuVax can acquire GE Healthcare’s intellectual property (IP) relating to an inactivated yellow fever vaccine. Under... Read more

March 22, 2016 Licensing, IP, and Legal

Takara Bio grants Cellectis SA a commercial license to use RetroNectin®

2016 2016/03/22 Takara Bio grants Cellectis SA a commercial license to use RetroNectin® Kusatsu/Shiga, Japan – March 22, 2016 – Takara Bio Inc. announces that it has entered into a License and Supply Agreement with Cellectis SA. Under the agreement, Takara Bio grants Cellectis a commercial license to use RetroNectin® and Takara Bio also supplies RetroNectin® to Cellectis . ... Read more

December 10, 2015 Bio/Pharma/CRO Licensing, IP, and Legal

NBA and GE Healthcare Leadership Meet on Injury Prevention, Diagnosis and Treatment

WAUWATOSA, Wis., Dec. 7, 2015 – The National Basketball Association (NBA) and GE Healthcare (NYSE: GE) today conducted a successful meeting at GE’s Wisconsin offices to discuss the progress of their research collaboration.  The partnership, which commenced in July, promotes sports medicine research to benefit not only NBA players but athletes of all levels.  Today’s... Read more

October 14, 2015 Licensing, IP, and Legal Product Launch

New Predatory Cockroaches (Insecta: Blattaria: Manipulatoridae fam.n.) from the Upper Cretaceous Myanmar Amber

We describe a new extinct lineage Manipulatoridae (new family) of cockroaches from the Upper Cretaceous (Cenomanian) amber of Myanmar. Manipulator modificaputis gen. et sp. n. is a morphologically unique extinct cockroach that represents the first (of a total of 29 known worldwide) cockroach family reported exclusively from the Myanmar amber. Read more